Summary A mathematical model was developed to improve understanding of the biodistribution and microscopic profiles of drugs and prodrugs in a system using enzyme-conjugated antibodies as part of a twostep method for cancer treatment. The use of monoclonal antibodies alone may lead to heterogeneous uptake within tumour tissue; the use of a second, low molecular weight agent may provide greater penetration into tumour tissue. This mathematical model was used to describe concentration profiles surrounding individual blood vessels within a tumour. From these profiles the area under the curve and specificity ratios were determined. By integrating these results spatially, average tissue concentrations were determined and compared with experimental results from three different systems in the literature: two using murine antibodies and one using humanised fusion proteins. The maximum enzyme conversion rate (Vmax) and the residual antibody concentration in the plasma and normal tissue were seen to be key determinants of drug concentration and drug-prodrug ratios in the tumour and other organs. Thus, longer time delays between the two injections, clearing the antibody from the bloodstream and the use of 'weaker' enzymes (lower Vmax) will be important factors in improving this prodrug approach. Of these, the model found the effective clearance of antibody outside of the tumour to be the most effective. The use of enzyme-conjugated antibodies may offer the following advantages over the bifunctional antibody-hapten system: (i) more uniform distribution of the active agent; (ii) higher concentrations possible for the active agent; and (iii) greater specificity (therapeutic index).
At present monoclonal antibodies have not realised their potential to treat solid tumours in patients (Sands, 1992) . Frequently, antibodies are not delivered uniformly or in adequate quantities in tumours (Jain, 1994) . On the other hand, traditional chemotherapeutic agents or radionuclides penetrate more rapidly throughout the tumour, but their toxic effects are not limited to cancer cells. For this reason two-step approaches to cancer therapy are being developed that seek to combine the specificity of monoclonal antibodies with the greater penetration and faster clearance of small molecules (e.g. Paganelli et Yuan et al., 1991) .
The use of enzyme-conjugated antibodies (ECAs; Figure 1 ) in combination with prodrugs is one promising two-step approach (Bagshawe et al., 1988; Senter et al., 1988 ). An antibody or antibody fragment that binds to a tumourassociated antigen is conjugated to an enzyme not present in the host and injected into the bloodstream. The ECA will penetrate tissues throughout the body, and after a few days or a week should be localised primarily within the tumour owing to high-affinity binding (albeit non-uniformly distributed; Yuan et al., 1991) . At this time a prodrug, which is a non-toxic precursor of a cytotoxic agent, is injected into the body. The role of the enzyme is to convert the prodrug back to the toxic form of the drug. Ideally, this will occur only where the enzyme is present, which is primarily in the tumour. The drug is then free to penetrate throughout the tumour, and the concentration levels in the blood and in normal tissues are minimised.
Previous studies by our group and others have shown the presence of a binding site barrier for high-affinity antibodies, which may prevent penetration of macromolecules in some regions of a tumour, on both macroscopic and microscopic length scales (Baxter and Jain, 1989 , 1991a Fujimori et al., 1989 Fujimori et al., , 1990 Sung et al., 1992; van Osdol et al., 1991; Weinstein and van Osdol, 1992) . The ECA-prodrug system is similar in some ways to the use of bifunctional antibodies (Le Received Doussal et al., 1990; Stickney et al., 1989 Stickney et al., , 1991 , for which we have also determined the microscopic distribution profiles (Baxter et al., 1992) . A specific application of the bifunctional antibody (BFA) system involving the high-affinity biotinstreptavidin system (Hnatowich et al., 1987; Paganelli et al., 1991) has also been recently modeled (Sung et al., 1994; van Osdol et al., 1993) . The BFA binds to a low molecular weight agent (referred to as a hapten in this manuscript), which may be cytotoxic itself, or radiolabelled. The three main differences between the use of bifunctional vs ECAs are: (i) the prodrug and drug molecules do not bind to the antibody or the tumour-associated antigen (other than to react), and so are not trapped in the tumour by any specific binding; (ii) a eAntibody Drug * (1. Enzyme w Prodrug Figure 1 Schematic of the enzyme-conjugated antibodyprodrug approach. A prodrug is converted to a more toxic form by an enzyme which has been linked to a monoclonal antibody that targets an antigen associated with the tumour tissue. There have been many experimental studies using ECA and prodrugs. Bagshawe and co-workers (Bagshawe, 1987; Bagshawe et al., 1988) have conjugated the enzyme carboxypeptidase and used a prodrug that is an aromatic nitrogen mustard linked to a glutamyl moiety. Senter et al. (1988) used an alkaline phosphatase enzyme and the prodrug etoposide phosphate (converted to etoposide). They found complete tumour regression in 40% of the animals whereas the administration of etoposide alone was ineffective. They used the same enzyme with mitomycin phosphate (Sahin et al., 1990; Senter, 1989) and phenol mustard phosphate (Wallace and Senter, 1991 For all the work done in this area of antibody-directed enzyme-prodrug therapy, comparatively little is known on the biodistribution of the various components. Smith and Thijssen (1986) have developed a preliminary mathematical (compartmental) model for the distribution of drugs following local activation. The first and most comprehensive experimental study on the biodistribution of active drugs after site-specific activation of prodrugs is by Antoniw et al. (1990) . They present data on the concentration of prodrug and drug, and enzyme activity, in nude mice bearing human CC3 choriocarcinoma xenografts, for plasma, tumour, liver, kidney and lung. Their system was A5B7F(ab')2 antibody fragment conjugated to carboxypeptidase G2, which converts a derivative of benzoic acid mustard to its active form. As the importance of in vivo transport issues has been acknowledged, more studies measuring the local concentrations of ECA and/or prodrug and drug have been published. Bosslet et al. (1992) (Antoniw et al., 1990; Bosslet et al., 1994; Wallace et al., 1994) . A key aim of developing this model was to provide a basis for the optimisation of ECA-prodrug therapy. The ability of models to provide novel insight for this approch is evidenced by this quote from Hellstr6m and Senter (1991) 'Yet another variable concerns the kinetics of drug release by the targeted enzyme. It would be of interest to test the validity of recent pharmacokinetic model studies suggesting that low turnover rates may result in higher tumour to blood drug ratios if the conjugate concentration in the tumour is higher than in the blood (Yuan et al., 1991 There is a no-flux boundary condition for mobile species at the surface of the cylinder (r= L) owing to symmetry with surrounding identical Krogh cylinders:
The boundary condition at the blood vessel wall relates the solute flux to the concentration gradient between the plasma (Cil1) and interstitial concentrations and the permeability (Pi) and partition (y,) coefficients (where yi is the ratio of the interstitial to plasma concentrations at equilibrium):
Equations must also be developed for the plasma concentrations. Following Baxter et al. (1992) we use a three-compartment model with saturable elimination to describe the pharmacokinetics of the low molecular weight agents and a two-compartment model for ECA, allowing for conversion of prodrug to drug in all compartments where enzyme is present:
where OA =0, /, = and 4D = -1, j represents the three compartments, with Kjk,i representing the transfer coefficient of species i from compartment j to k and K,0 is the rate constant for elimination from the plasma (e.g. via urine). These compartmental transfer coefficients may be obtained from the coefficients of the following expression that provides the best fit to experimental data for the plasma concentration (Cil) of free species (Gibaldi and Perrier, 1982) . For the antibody, a biexponential fit was sufficient to describe the plasma pharmacokinetics. Without further physiological information on ECA distribution, and with the smaller prodrug able to move between the shallow and deep compartments, it was assumed that there was no ECA in the deep compartment, and hence no prodrug conversion. (Additional simulations without this assumption resulted in no significant change in drug concentration in the tumour or plasma.) 0Cii a1 exp-Alt ±+ A2 exp-A2t
The initial conditions are zero concentrations in the plasma and tissues for all species, with a step change in the plasma antibody concentration at t = 0 + to Cp°= dose/plasma volume. Similarly when the prodrug is introduced there is a step change at t = T from 0 to its initial plasma concentration.
In the model we have not attempted to incorporate pharmacodynamic effects, cellular internalisation or metabolism. These effects, while important, vary tremendously from one prodrug/drug system to another (e.g. depending upon hydrophilicity, membrane transport, charge, mode of action etc.) The model equations could be modified to incorporate these effects for a specific drug but the equations above are meant to be general for a system in which the concentration at the site of action is proportional to the interstitial concentration. The simulations were based on a bolus injection of ECA 72 h before prodrug administration. The equations given above were solved numerically using the IMSL subroutine DMOLCH, which uses the method of lines with cubic hermite polynomials to solve a system of ordinary differential equations obtained from a centered finite difference approximation of the partial differential equations for diffusion (IMSL, 1987) .
In order to determine the effects of relevant physiological parameters on the uptake and distribution of ECA and drug we have carried out additional simulations varying each of the important parameters. To allow comparison of different conditions, each profile is analysed to calculate the average concentration (<C>), area under the concentration -time curve (AUC) for plasma and tumour. Since the ECA-prodrug system may be beneficial only for therapy and not detection, the instantaneous tumour-plasma level (specificity ratio) is not as important as the relative total exposure to the drug, i.e. the therapeutic index (TI=AUCtumour/AUCp1asma). As in Baxter et al. (1992) we have calculated an index of spatial uniformity (UNI), which is equal to the volume around the blood vessel in which one-half of the ECA or drug has distributed, divided by the equivalent volume under a uniform distribution. Thus UNI, a function of time, approaches zero when all the material is just outside of the blood vessel and approaches unity for a uniform interstitial distribution. The role of cellular uptake or elimination of antibody may vary greatly from system to system. To study the effect of antigen internalisation and/or antibody metabolism on the resulting drug distribution in the ECA system we have included a simulation with ke = 1.9 day-l (as used in Baxter and Jain, 1991a; Baxter et al., 1992) . Figure 2 shows the model simulations for the baseline parameters for the prodrug and drug distribution in which the prodrug is injected 3 days after ECA administration. The spatial distribution is plotted for a series of time points. Note that both the prodrug and drug concentration profiles are quite uniform even at early time points. This is in contrast with the profiles in Figure 3 , which show the ECA concentration as well as the hapten concentration following BFA administration with the model from (Baxter et al., 1992) . In this figure, the antibody concentrations are essentially constant over the short time that the drug is present. The hapten molecules are mostly bound to the antibody (for low hapten doses, and after the rapid clearance phase for higher doses). Thus the perivascular hapten distribution tends to mimic the antibody distribution. It is also seen that the prodrug and drug molecules clear from the body much more rapidly as they do not bind to the ECA (as in the BFA-hapten approach). The main reason for the very uniform profiles is that the conversion rate >> diffusion rate >> permeability rate for molecules of this size in the r9 449 Microscopic model for ECA-prodrug therapy LT Baxter and RK Jain 450 presence of a specific enzyme. Figure 4 shows the plasma and tumour concentrations for both drug and prodrug as a function of time. The drug levels are highest in the tumour, where the conversion rates are greatest; hence the prodrug levels in the tumour are less than in the plasma. It can be seen that significant (and detrimental) conversion occurs outside of the tumour for the baseline parameters.
Results

Baseline simulations
Sensitivity analysis Other simulations were carried out to determine the effect of various parameters on the drug biodistribution: changes in permeability, diffusivity, binding affinity, kinetic rate constants and the time delay between ECA and prodrug injections. The effect of clearing all antibody from outside the tumour (via plasmapheresis or a chasing antibody) was also studied. The concentration profiles for the prodrug and drug were analysed as described above to yield information on the tumour to plasma concentration ratios (T/P), average concentrations <C>, therapeutic index (TI) and perivascular uniformity index (UNI). The results are given in These simulations show that the parameters with the greatest effect on the therapeutic index are the Vmax enzyme rate constant, the time interval before prodrug injection and the reduction in the plasma ECA concentration. All of these parameters are reflections of the requirement to minimise prodrug conversion outside of the tumour, rather than obtain the highest possible conversion or concentration within the tumour. Parameters that affect the therapeutic index to a lesser degree are ECA molecular weight, binding affinity and antibody dose (Table II) aBaseline value is zero, but the simulation which includes metabolism uses a value of 2.17 x 10-5 S-1 (Baxter and Jain, 1991a Table I . different groups that contain sufficient information (data and parameters) to compare with our model (Antoniw et al., 1990; Bosslet et al., 1994; Wallace et al., 1994) . These three studies look at different ECA and prodrug systems in nude mice. All have taken some measures to address the problem of non-specific conversion of prodrug outside the tumour. Antoniw et al. Bosslet et al. (1994) use long time intervals before prodrug administration (6 and 7 days respectively), whereas Wallace et al. (1994) use an antiidiotypic antibody to clear the ECA from the bloodstream. Bosslet et al. (1994) also used an enzyme with a relatively low Vmax. In the simulations described below, baseline parameters were used unless different parameters were given in the experimental study.
Carboxypeptidase G2-benzoic acid mustard Antoniw et al. (1990) were the first to present the pharmacokinetics of ECA, prodrug and drug together. They used carboxypeptidase G2 conjugated to F(ab')2-anti-human chorionic gonadotropin antibody W14A to convert the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid to its activated derivative, benzoic acid mustard. The prodrug was administered (41 ,umol kg-' i.p.) to mice bearing human CC3 choriocarcir(gm) flow limited in the tumour, i.e. the uptake may be affected average of vascular, intersitial and cellular fractions. Hence, not by the permeability but by the regional blood flow rates the estimated yi is not necessarily the same as the true (Yuan et al., 1993) . Third, the tumour may have necrotic or equilibrium partition coefficient. poorly perfused regions that have little or no blood supply and hence reduced availability of prodrug. Fourth, the extent to which the prodrug and drug are internalised by cells will have an effect on the measured concentration, which is an Time (min) Figure 4 Plasma concentrations of prodrug and drug are plotted as a function of time, 3 days after injection of ECA. The same baseline parameters were used (Table I) . In addition, ECA with prodrug is also not used for cancer detection. Exact quantitative agreement between these simulations and experimental data has been hindered by the assumption of homogeneous transport properties throughout all regions of a tumour and by the simplified plasma pharmacokinetic model (and transcapillary exchange) used, as has been addressed elsewhere (Jain and Baxter, 1988; Baxter and Jain, 1989; Strand et al., 1993; Baxter et al., 1994 Baxter et al., , 1995 
